Studies On The Safety And Efficacy Of Early Antiplatelet Therapy In Patients Of Cerebral Hemorrhage With High Risk Factors Of Ischemic Events

The first part Study on the safety and efficacy of early antiplatelet therapy in patients of cerebral hemorrhage with high risk factors of ischemic eventsObjective Patients with ischemic cardio-cerebrovascular disease often need antiplatelet therapy,this study mainly discusses the safety,efficacy and time of use of antiplatelet drugs in patients with high risk of ischemic cardio-cerebrovascular disease.Method The survivors of hypertensive intracerebral hemorrhage from 2016 to 2017 were selected as the subjects,and the patients were divided into placebo group,early intervention group and advanced intervention group.The placebo group were treated with placebos(75 mg)after the hematoma were absorbed,early intervention group were treated with clopidogrel sulfate tablets(75 mg)after the absorption of hematoma,and advanced intervention group were treated with clopidogrel sulfate tablets(75 mg)after 1 months of hematoma absorption.Followed 12 months.The general information of admission group patients and the occurrence of ischemic events and bleeding events during the follow-up were recorded.Result There were no significant differences in bleeding event between placebo group and early intervention group within 3 months(P>0.05).There were no significant differences in bleeding events between the three groups within 12 months(P>0.05).The incidence of ischemic events in the placebo group was higher than that in early intervention group and advanced intervention group within 12 months,and the differences were statistically significant(P<0.05).The incidence of ischemic events in placebo group and advanced intervention group were higher than that in early intervention group,and the differences were statistically significant(P<0.05).Conclusion There were safe and effective to receive antiplatelet drugs in early stage after hypertensive intracerebral hemorrhage in patients with high risk cardiovascular and cerebrovascular diseases.Among them,use of antiplatelet drugs after hematoma absorption are more effective in reducing the incidence of ischemic events than 1 months of hematoma absorption,and do not increase the risk of bleeding.The Second part Analysis of the relationship between serum cystatin C and intracerebral hemorrhageObjective Investigate the relationship between serum Cystatin C and intracerebral hemorrhage.Method 115 patients with intracerebral hemorrhage in our department were treated as observation group and 71 healthy patients were treated as control group.The serum Cys C,CRP,UA,TC,TG,LDL-C and HDL-C in the observation group and control group were detected respectively,and the effects of these factors on cerebral hemorrhage were analyzed.The relationship between serum Cys C level and cerebral hemorrhage were analyzed.Result The levels of serum Cys C(0.82±0.27)mg/l in intracerebral hemorrhage Group was higher than that in control group(0.68±0.19)mg/l,and the differences were statistically significant(P<0.05),and serum Cys C was the independent risk factor of cerebral hemorrhage by multivariate logistic regression analysis.Conclusion The results showed that serum Cys C levels was an independent risk factor for ICH,the higher Cys C level,the greater risk of ICH occurrence.